Skip to content
PICO Portalanswers from OpenAlex

Tofacitinib Ameliorates Lipopolysaccharide‐Induced Acute Kidney Injury by Blocking the JAK‐STAT1/STAT3 Signaling Pathway

PaperCitations, authors & open-access status

Tofacitinib Ameliorates Lipopolysaccharide‐Induced Acute Kidney Injury by Blocking the JAK‐STAT1/STAT3 Signaling Pathway is a paper indexed in PICO Portal from OpenAlex.

How many citations does Tofacitinib Ameliorates Lipopolysaccharide‐Induced Acute Kidney Injury by Blocking the JAK‐STAT1/STAT3 Signaling Pathway have?

PICO Portalcitation count

Tofacitinib Ameliorates Lipopolysaccharide‐Induced Acute Kidney Injury by Blocking the JAK‐STAT1/STAT3 Signaling Pathway has 31 citations in the OpenAlex counts PICO Portal stores.

When was Tofacitinib Ameliorates Lipopolysaccharide‐Induced Acute Kidney Injury by Blocking the JAK‐STAT1/STAT3 Signaling Pathway published?

PICO Portalyear

Tofacitinib Ameliorates Lipopolysaccharide‐Induced Acute Kidney Injury by Blocking the JAK‐STAT1/STAT3 Signaling Pathway has 2021 year in the PICO Portal index.

What is the open-access status of Tofacitinib Ameliorates Lipopolysaccharide‐Induced Acute Kidney Injury by Blocking the JAK‐STAT1/STAT3 Signaling Pathway?

PICO Portaloa status

Tofacitinib Ameliorates Lipopolysaccharide‐Induced Acute Kidney Injury by Blocking the JAK‐STAT1/STAT3 Signaling Pathway has hybrid oa status in the PICO Portal index.

What is the DOI of Tofacitinib Ameliorates Lipopolysaccharide‐Induced Acute Kidney Injury by Blocking the JAK‐STAT1/STAT3 Signaling Pathway?

PICO Portaldoi

The DOI for Tofacitinib Ameliorates Lipopolysaccharide‐Induced Acute Kidney Injury by Blocking the JAK‐STAT1/STAT3 Signaling Pathway is on the source record.

What is the PMID of Tofacitinib Ameliorates Lipopolysaccharide‐Induced Acute Kidney Injury by Blocking the JAK‐STAT1/STAT3 Signaling Pathway?

PICO Portalpmid

The PMID for Tofacitinib Ameliorates Lipopolysaccharide‐Induced Acute Kidney Injury by Blocking the JAK‐STAT1/STAT3 Signaling Pathway is on the source record.

What is the OpenAlex record for Tofacitinib Ameliorates Lipopolysaccharide‐Induced Acute Kidney Injury by Blocking the JAK‐STAT1/STAT3 Signaling Pathway?

PICO Portalopenalex

The OpenAlex for Tofacitinib Ameliorates Lipopolysaccharide‐Induced Acute Kidney Injury by Blocking the JAK‐STAT1/STAT3 Signaling Pathway is on the source record.

Related on PICO Portal

470M+ articles · 14-day free trial